Jun 08, 2018 -
CureMatch is a small startup that's making a huge impact in the world of precision medicine by developing the advanced technology to 'match' cancer treatments specific to an individual patient. Its software reviews more than 4.5 million different combinations of anti-cancer drugs to find the combination best suited to fight against the patient's unique molecular tumor profile. This incredible technology enables oncologists to become experts in personalized medicine by providing them with actionable intelligence towards advanced cancer treatment options.
CureMatch won the MetroConnect Grand Prize, an annual competition hosted by World Trade Center San Diego, which will help them bring their life-changing, life-saving technology into Canadian, Mexican, and European markets.
The cash, awarded last Thursday, was the grand prize in the annual MetroConnect contest organized by the World Trade Center San Diego, an affiliate of the San Diego Regional Economic Development Corp. CureMatch CEO Stephane Richard (in photo above) said the company would use the award to expand into Canada, Mexico, and Europe.
San Diego is central to CureMatch's story. The company worked with the world-renowned Moore's Cancer Center at UC San Diego Health and also partnered with the San Diego Supercomputer Center to ensure they can deliver comprehensive cancer analysis (and save more lives!) faster.
"San Diego is one of the few places in the world where a company like CureMatch could happen," said Bob Manning, director of marketing at CureMatch.
But the San Diego story is the bi-national story, so CureMatch is taking it one step further. Partnering with the Oncologic Pediatric Center of Baja California (Centro Oncologico Pediatrico de B.C.), CureMatch is providing a free analysis to every pediatric cancer patient in Northern Baja Mexico.
Read more in the Xconomy article here.